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Abstract 
Introduction 
Digital ulcers (DUs) are a major 
clinical problem for patients with 
systemic sclerosis (SSc). Almost half of 
SSc patients experience at least one 
acral DU during the course of the 
disease. Patients with DUs may suffer 
from severe pain and often undergo a 
limitation of daily life activities, thus 
resulting in a functional impairment 
with a significant impact on the 
patient’s health-related quality of life. 
Prevention of further complications 
and lesions is possible if the initial 
evaluation is performed early and 
correctly and if a treatment is started 
promptly. Pharmacologic treatment is 
important, but it is not the only 
possible approach to patients with 
DUs. This review provides an 
overview of the available different 
treatment options for DUs together 
with a proposal of a diagnostic-
therapeutic approach aimed at a 
better definition and treatment of 
patients with SSc and DUs. 
Discussion 
A correct approach to the patient with 
DUs begins with a careful examination 
and evaluation of risk factors and 
comorbidities in order to cure and 
prevent complications and further 
lesions. Then also a correct local 
treatment of the DU provides a better 
milieu to foster healing and prevent 
complications such as infection or 
gangrene. Different drugs with 
different mechanisms of action are to 
date available for the treatment and 
prevention of DUs in SSc, but it will be 
swiftly effective only if in combination 
with good information of the patient 
and a thorough local treatment of the 
ulcers. 
Conclusion 
A correct therapeutic approach can be 
based only on a correct education and 
information of the patient. 
  
Introduction 
Digital ulcers (DUs) are a major 
clinical problem for patients with 
limited or diffuse systemic sclerosis 
(SSc) and a recurrent challenge for 
rheumatologists. About half of 
patients with SSc experience at least 
one acral DU during the course of the 
disease1. Patients with DUs may suffer 
from severe pain and often undergo a 
limitation of daily life activities, thus 
resulting in a functional impairment 
with a significant impact on the 
patient’s health-related quality of life 
(HRQoL)2. The aim of this review is to 
provide the reader with an overview 
of the currently available approaches 
for the management of DUs in SSc and 
to propose a step-by-step diagnostic 
and therapeutic flow-chart, based on 
uptodate evidence and the personal 
experience of our team. 
  
Characteristics and terminology 
Pure DUs are usually punctiform, very 
painful, they develop mainly in the 
fingers or toes, usually on the tips, but 
they may also involve skin creases, 
over the proximal interphalangeal 
(PIP) joints3. 
 
The definition of DU has been a 
problem for a long time, until a very 
recent consensus approach has 
attempted to find a more precise 
classification3 for use in observational 
studies or randomized clinical trials 
(RCTs). Based on this classification, a 
DU is a lesion with loss of continuity of 
epithelial coverage, which can be 
denuded, with discernible and 
measurable depth or covered by a 
scab or crust (i.e. a hardened covering 
of dried secretions such as blood, 
plasma or pus) or necrotic tissue (i.e. a 
black or dark brown remnant of 
normal tissue that has become necrotic 
because of the ischemia of that area)3. 
Following this classification, only DUs 
at or distal to PIP joints and without 
bone infection or calcinosis are to be 
assessed. DUs do not include fissures, 
paronychia, extrusion of calcium, ulcers 
over calcium nor ulcers over the 
metacarpophalangeal joints or elbows3. 
DUs at or distal to PIP joints may be 
traumatic and the actual contribution of 
SSc vasculopathy is still to be 
determined, thus it is up to the 
designers of the trials to decide 
whether to include these DUs in the 
trial or not3. 
 
Active ulcers are those in which 
denudation is clearly visible at any part 
of the base and de-epithelialization can 
be observed. Indeterminate ulcers are 
those in which the examiner is not able 
to evaluate the presence of a de-
epithelialized base. Healed ulcers are 
those with a complete re-
epithelialization, also in the form of an 
atrophic hypopigmented area. 
 
Possible complications of DUs are 
infections, osteomyelitis, gangrene or 
amputation as shown in figure 1. 
Gangrene occurs more frequently in 
diffuse SSc, possibly related to a major 
vascular involvement4. Gangrenous 
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Figure 1: Multiple digital ulcers of the 
fingers with associated gangrene and bone 
exposure leading to auto-amputation. 
 
Page 2 of 6 
Licensee OAPL (UK) 2014. Creative Commons Attribution License (CC-BY) 
FOR CITATION PURPOSES: Gualtierotti R, Adorni G, Lubatti C, Zeni S, Meroni PL, Ingegnoli F. Digital ulcer 




















































































































































































shrunken and dark or black should 
not be considered DUs. Even when the 
lesions do not meet yet the definition 
of gangrene, but encircle the fingertip 
(excluding the nail), they should not 
be considered as DUs in a trial, 
because the healing of these lesions 
may be very complicated and perhaps 
unlikely until the digital tip auto-
amputates, thus introducing an 
unwanted bias (Figure 2). 
 
Etiopathogenesis 
DUs are a manifestation of the 
underlying vasculopathy and fibrosis 
that characterize SSc. They are almost 
always associated with Raynaud’s 
phenomenon (RP), a vasospasm in 
response to cold or emotion resulting 
in impaired oxygenation of the distal 
extremities (Figure 3)2. The 
underlying pathogenetic mechanisms 
of DUs in SSc are multiple, such as 
microtrauma, sclerodactyly and dry 
skin, but the vasculopathy that 
characterizes SSc is believed to play a 
pivotal role. Although the triggering 
factors are still unknown2, the initial 
endothelial injury is accompanied by 
an increase in the levels of endothelin-
1 (ET-1), a peptide with 
vasoconstrictor effects mediated by 
endothelin type A (ETa) receptors 
present on vascular smooth-muscle 
cells (SMCs) causing vasoconstriction 
and vascular remodelling effects, and 
by means of endothelin type B (ETb) 
receptors, present on endothelial cells 
and SMCs with vasodilating effects2,5. 
Alternatively, endothelial cells may be 
injured by the presence of endothelial 
cell antibodies, which would imply 
platelet activation with release of 
thromboxane and eventually 
intraluminal thrombosis5. The 
subsequent migration of SMCs into the 
intimal layer of the microvasculature 
and differentiation into 
myofibroblasts producing collagen 
and other extracellular matrix are 
responsible for the intimal 
proliferation with fibrosis, thus 
leading to a fixed narrowing of the 
intravascular lumen and causing 




The authors have referenced some of 
their own studies in this review. These 
referenced studies have been 
conducted in accordance with the 
Declaration of Helsinki (1964) and the 
protocols of these studies have been 
approved by the relevant ethics 
committees related to the institution 
in which they were performed. All 
human subjects, in these referenced 
studies, gave informed consent to 
participate in these studies. 
  
Evaluation 
As shown in figure 1, the evaluation of a 
patient with DUs should start from the 
patient’s history, which should be 
aimed at finding risk factors which may 
favour the development of DUs such as 
thrombophilia, dislipidemia, 
hyperchortisolism, dehydration, 
traumas, neoplasias, autoimmune 
pathology, smoke, drugs that may 
favour vasoconstriction. Physical 
examination should evaluate 
localization, depth, boundaries, 
presence of fibrin, debris, granulation 
 
 Figure 2: Multiple digital ulcers of the fingers (arrows) and a fissure 
(star). 
 
 Figure 3: Raynaud’s phenomenon: ischemic phase of one digit (middle finger). 
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tissue, calcinosis, necrosis, gangrene, 
pus, blood on the de-epithelialized 
basis. The presence of pus and severe 
pain is invariably associated with 
infection. Also severe pain is 
significantly associated with 
infection4. When associated to 
gangrene, concomitant DUs may be 
very deep and accompanied by 
perilesional oedema, inflammation 
and presenting, not rarely, with bone 
and tendon exposure (Figure 1). 
 
Therapeutic approach 
The treatment of DUs must parallel 
the treatment of RP with or without 
ischaemic complications. A possible 
approach to treat patients with DUs 
and/or RP is shown in figure 4. It is 
pivotal to have a good skin care in 
order to promote healing, basing the 
choice of the dressings depending on 
the presence or absence of infection 
and other factors (Table 1). To foster 
DU healing, surgical debridement is 
often required. The presence of fibrin, 
oedema or inflammation, necrosis, 
eschars or gangrene delays 
significantly the time to healing7,8. 
Ischaemia involving the whole distal 
phalanx needs hospitalizations for 
aggressive treatment9,10,11. 
Clinicians should start helping 
patients in managing pain, which has 
considerable impact on HRQoL12 and 
further triggers vasoconstriction5. 
Secondary prevention, i.e. prevention 
of further lesions, by minimizing the 
occurrence of minor trauma as well as 
prevention of complications is very 
important. It is important to restore 
hand function, improve digital 
circulation, prevent infection and 
promote healing. 
 
Whenever a macrovascular disease 
underlying or contributing to the 
ischaemic digital process is suspected, 
an ultrasonographic Doppler study of 
the vessels or an angiography should 
be performed13. 
 
Primary prevention and lifestyle 
changes 
Avoidance of cold temperatures by 
means of proper garments and gloves, 
hats, heavy socks, should be sought 
not only during cold seasons, but in all 
the cases required by a cold external 
temperature (e.g. refrigerators in a 
supermarket; cold temperature in hot 
seasons due to sudden weather 
changes, etc.). Stress is another trigger 
for vasospasm in RP. Although there 
are not enough data to support the 
use of techniques such as conditioning, 
biofeedback and relaxation techniques 
in SSc patients14, the high prevalence of 
anxiety and depression in these 
patients requires careful examination 
of the psychologic conditions of the 
patients with SSc and, if necessary, the 
use of anti-depressants or anxiolytics. 
Patients should also be taught to use 
topical hydrating creams in order to 
maintain skin moist.  
 
Whenever possible, trauma to the digits 
should be avoided, such as working in a 
cold environment (e.g. fridge aisle, etc) 
or repetitive hand working (e.g. typing). 
Smoking should be avoided even if 
there is a lack of univocal data 
regarding its pathogenic role in 
Raynaud’s triggering. 
  
Supportive care and local treatment 
Pain control should not be overlooked 
by physicians, not only for 
improvement of their HRQoL, but also 
in order to avoid further vasospasm 
generated by the adreno-receptors that 
may worsen the ischemic condition5. 
Pain management should be started 
quickly and adjusted on the patient 
needs. Acetaminophen and opiates 
should be preferred5. If infection is 
suspected, a specific antibiotic should 
be started, based on antibiogram. If 
osteomyelitis is suspected, prompt 
treatment with i.v. antibiotics should be 
started. 
 
Semi-occlusive wound dressings 
prevent evaporative water loss and 
retain warmth, which improves wound 
healing15. Table 1 shows the most 
commonly used wound dressings and 
their different indications. Antiseptics 
should be avoided because of the 
known cytotoxic effects on cells and 
local antibiotics may induce the 
emergence of resistance to the entire 
class of antibiotics used topically. 
Ulcers must be cleaned with 
physiologic water. The use of systemic 
antibiotics should be reserved only for 
clinically infected ulcers and not for 
bacterial colonization15. Debridement is 
important because the removal of 
necrotic tissue and sloughs have been 
demonstrated to be effective in 
accelerating wound healing15. 
 
Figure 4: The flow-chart shows the proposed approach to digital ulcers in 
systemic sclerosis (AB: antibiotic therapy, DU: digital ulcer; ERA: endothelin 
receptor antagonist; i.v.: intravenous). 
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Debridement can be mechanical via 
curette or scalpel, or chemical, via 
enzyme-debriding agents such as 
collagenase, papain, trypsin. D-alpha-
tocopheryl acetate (acetic ester of 
alpha-tocopherol) gel on DUs of SSc 
patients treated twice a week was 
shown to induce a faster healing of 
DUs, with a faster resolution of pain 
and a lower cost of medications in 
respect to controls with a lower 
number of medications16. 
  
Pharmacological therapy 
Despite the substantial impact that 
SSc-DUs have on function and HRQoL, 
currently there is no widely accepted 
therapeutic algorithm. 
Prostacyclin analogues 
In Europe, cyclic use of i.v.iloprost is 
the standard of care for the treatment 
of ischemically threatened digits and 
severe SSc DUs. The most robust study 
supporting the use of iloprost is a 
multicenter trial in patients with SSc 
and RP17. After three weeks, 14.6% 
more patients receiving i.v. 6-hour 
infusion of iloprost (dose 0.5-2 
ng/kg/minute) for five days had 50% 
or more lesions healed compared with 
those given placebo. A trend was also 
observed towards prevention or 
reduction of the formation of new DUs 
(25% of the patients had new lesions 
after iloprost compared with 33% of 
the patients receiving placebo). A 
Cochrane review also concluded that 
i.v. iloprost is effective in the 
treatment of RP secondary to SSc at 
decreasing the frequency and severity 
of the attacks and in preventing or 
healing DUs. The effect seems to be 
prolonged after the intravenous 
infusion is given. Oral prostanoids 
may have minimal or no efficacy for 
the treatment of RP secondary to 
SSc18. Other prostacycline analogues 
such as epoprostenol and beraprost 
demonstrated no efficacy in DU 
healing, although trends towards a 
decrease in the number of new DUs 
were observed with both drugs19,20. By 
contrast, subcutaneous treprostinil 
showed efficacy in both healing and 
preventing DUs, but its use is limited 
by the acute injection site pain21. An 
ongoing phase II double blinded 
multicenter RCT of oral treprostinil in 
SSc DUs is currently recruiting. 
Calcium channel blockers (CCBs) 
CCBs act on vascular SMCs to cause 
arterial vasodilation. A small RCT 
compared oral nifedipine at 30 to 60 
mg dosage, with i.v.iloprost in patients 
with SSc and RP, who were severely 
affected by skin lesions (ulcers, 
fissures or paronychia), 
demonstrating a decrease in the mean 
number of digital lesions. The 
limitations of this study are the small 
number of patients, the lack of clear 
baseline number of DUs per patient 
and the use of different skin lesions 
apart from ulcers as outcome 
measure22. 
Endothelin receptor antagonists 
(ERAs) 
Bosentan was initially developed for 
pulmonary hypertension and was 
found to be useful in the prevention of 
the onset of new lesions in SSc 
patients who had already experienced 
DUs but seems to have no effect in 
healing of the existing ulcers23,24. The 
RAPIDS-2 study confirmed bosentan 
effects on prevention of new DUs in SSc 
patients, particularly in those with 
multiple DUs (at least four as suggested 
by the Authors) not receiving i.v. 
prostacyclin analogues or 
phosphodiesterase-5 (PDE-5) 
inhibitors in the previous three months, 
but also confirmed the absence of 
efficacy in the healing of pre-existing 
DUs25. Therefore, the use of bosentan is 
indicated as secondary prevention in 
those patients presenting with multiple 
DUs. The incidence of liver 
aminotransferase elevation requires 
tight monitoring of blood tests25. 
PDE-5 inhibitors (PDE5I) 
PDE5I induce vasodilation by 
increasing the levels of endogenous 
nitric oxide (NO). Case reports, case 
series and a meta-analysis indicate a 
benefit of sildenafil on SSc-DUs24,26,27. In 
an open-label study on 19 patients with 
49 DUs present at baseline, the number 
of DUs decreased to 17 after a 6-month 
therapy with sildenafil, although a total 
of 9 patients developed 12 new DUs 
during sildenafil treatment28. The 
effects of tadalafil on DUs were shown 
in a study on 25 SSc patients. Although 
the patients were receiving also other 
therapies for RP and the healing and 
prevention of DUs were secondary 
outcomes, the results were promising: 
all the 24 digital lesions healed during 
tadalafil therapy as compared with 3 on 
13 during the placebo treatment. One 
new DU was reported during tadalafil 
therapy vs 13 during placebo therapy29. 
Significant adverse events are 
headache, myalgia, priapism, allergic 
reactions, chest pain and others24. 
Table 1: Wound care dressings and their main indications. 
Type of dressing Healing stage 
Hydrocolloids Mildly exuding ulcer 
Alginates Debridement 
Hydrogels Necrotic ulcer, dry ulcer 
Hydrofibers Infected ulcer, heavily exuding ulcer (debridement stage) 
Impregnated or coated meshes Mildly exuding ulcers, alteres peripheral wound skin 
Foam dressings Heavily exuding ulcers, granulating ulcers, altered peripheral wound skin 
Hyaluronic acid-based dressings Mildly exuding ulcer 
Charcoal dressings Foul-smelling ulcer 
Silver-coated dressings Infected ulcer, foul-smelling ulcer 
Protease-modulating dressings Hard-to-heal ulcer 
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There is a lack of evidence for the 
efficacy of other drugs such as N-
acetylcysteine, angiotensin converting 
enzyme inhibitors, angiotensin II 
receptor blocking agents, nitrates and 
statins. A Cochrane review of prazosin 
demonstrated efficacy versus placebo, 
but the efficacy is modest and side 
effects limit its use. While there is no 
evidence that aspirin may accelerate 
DU healing, beneficial effects of low 
molecular weight heparin were 
observed in severe RP patients30. 
The role of the surgeon for DUs 
A surgical consult may be necessary in 
the case of failure of the medical 
approaches and thus it is a pivotal 
intervention not only in the case of 
macrovascular disease. To foster DU 
healing, surgical debridement may be 
required. As shown in figure 1, a 
surgical opinion should be sought 
whenever a macrovascular 
involvement is suspected and, if 
necessary, also arteriography could be 
performed, both with diagnostic and 
therapeutic aims. For patients who do 
not respond to the above mentioned 
interventions, a surgical approach in 
order to inhibit vasoconstriction and 
to improve blood flow to the 




Management of DUs in SSc must be 
based on a complex approach which 
comprehends the treatment of blood 
flow reduction, vasculopathy, possible 
thrombosis of the vessels involved, 
antibiotic therapy if necessary and 
local treatment of DUs. Prevention 
should not be left behind: patients 
should be taught to refer to their 
rheumatologist as soon as signs or 
symptoms of critical digital ischemia 
present, as well as in case of DU 
appearance and to lifestyle and 
hygienic rules that patients should 
follow even in the case of a mute 
history for digital ischemia or DUs. A 
correct therapeutic approach can be 
based only on a correct education and 
information of the patient. 
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